María Belen Bouzas

Dr. María Belen Bouzas

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMaría Verónica Pineda
María Verónica Pineda
MBMaría Belen Bouzas
María Belen Bouzas
MRMirta Remesar
Mirta Remesar
AFAriel Fridman
Ariel Fridman
CRCarlos Remondegui
Carlos Remondegui
AMAndrea Mangano
Andrea Mangano
HTLV-1 proviral load (pVL) in peripheral blood mononuclear cell (PBMCs) is proposed as a marker of disease progression but its role still remains controversial. The aim of this study was to evaluate the levels of HTLV-1 pVL in symptomatic patients and asymptomatic HTLV-1 carriers. In this cross-sectional study the pVL was measured by Real Time PCR in 102 asymptomatic carriers and 22 symptomatic patients (5ATLL, 15 TSP and 2 uveitis). We observed that the HTLV-1 pVL was significantly higher in symptomatic patients (median = 4.99 log10 HTLV-1 copies /106 PBMCs) compared to asymptomatic HTLV-1 carriers (median = 4.38 log10 HTLV-1 copies /106 PBMCs; p = 0.0030). A wide variation on the HTLV-1 pVL levels among asymptomatic HTLV-1 carriers was observed with some pVL as high as those observed in symptomatic patients. The asymptomatic HTLV-1 carriers were divided according to the place of birth and the highest levels of pVL were detected among patients from endemics areas from the North of Argentina. Our results reinforce the usefulness of the proviral load would be a prognostic marker of HTLV-1 disease progression. Moreover, host, viral or socio-environmental factors cannot be excluded as determinant of high proviral load.

12 September 2023 in Viruses
Verified
Journal Article
Open access
PDF file
SWSANTIAGO Werbajh
SANTIAGO Werbajh
LLLuciana Larocca
Luciana Larocca
CCCarolina Carrillo
Carolina Carrillo
FSFabiana Stolowicz
Fabiana Stolowicz
LCLorena Ogas Castells
Lorena Ogas Castells
AVAdrián Alberto Vojnov
Adrián Alberto Vojnov
Since, during the Coronavirus disease 19 (COVID-19) pandemic, a large part of the human population has become infected, a rapid and simple diagnostic method has been necessary to detect its causative agent, the Severe Acute Respiratory Syndrome-related Coronavirus-2 (SARS-CoV-2), and control its spread. Thus, in the present study, we developed a colorimetric reverse transcription-loop-mediated isothermal amplification (RT-LAMP) kit that allows the detection of SARS-CoV-2 from nasopharyngeal swab samples without the need for RNA extraction. The kit utilizes three sets of LAMP primers targeting two regions of ORF1ab and one region in the E gene. The results are based on the colorimetric change of hydroxynaphthol blue, which allows visual interpretation without needing an expensive instrument. The kit demonstrated sensitivity to detect between 50 and 100 copies of the viral genome per reaction. The kit was authorized by the National Administration of Drugs, Food and Technology (ANMAT) of Argentina after validation using samples previously analyzed by the gold standard RT-qPCR. The results showed a sensitivity of 90.6% and specificity of 100%, consistent with conventional RT-qPCR. In silico analysis confirmed the recognition of SARS-CoV-2 variants of concern (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427, and B.1.429), and lineages of the Omicron variant (B.1.1.529) with 100% homology. This rapid, simple, and sensitive RT-LAMP method paves the way for a large screening strategy to be carried out at locations lacking sophisticated instrumental and trained staff, as it particularly happens in regional hospitals and medical centers from rural areas.

1 August 2024 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
NLNatalia Laufer
Natalia Laufer
MBMaría Belen Bouzas
María Belen Bouzas
SGSilvina Fernández Giuliano
Silvina Fernández Giuliano
IZInes Zapiola
Ines Zapiola
LMLilia Mammana
Lilia Mammana
SMSergio Martini
Sergio Martini
Introduction: More than 62.000 individuals are currently on antiretroviral treatment within the public health system in Argentina. In 2019, more than 50% of people on ART received NNRTIs. Objectives: To assess the prevalence of HIV-1 drug resistance in Argentina using the WHO guidelines. Methods: This was a nationwide cross-sectional study enrolling consecutive 18 year-old and older individuals starting ARVs at 19 ARV-dispensing centers. This allowed us to estimate a point prevalence rate of resistance-associated mutations (RAMs) with a CI of 5% (for the total population and for those without antiretroviral exposure). Results: Four-hundred forty-seven individuals were included in the study. The prevalence of mutations associated with resistance was detected in 27.7% (95 CI 25.6-34.9%) of the population. For NNRTI, it was 19.6% (CI 95 16.3-24.5%), for INSTI 6.1% (CI95 6.1-11.9%), for NRTI 3% (CI95 1.9-5.9%) and for PI 1.5% (CI95 0.7-3.6%). Naive individuals had variants of resistance to NRTIs in 16.8% (CI95 12.8-21.4) and 5.7% (CI95 2.9-15.9) to INSTI. For experienced individuals, the prevalence of variants associated with resistance was 30.38% (95 CI 20.8-42.2) for NRTIs and 7.7% (CI 95 2.9-15.9) for INSTI. Conclusions: The second study conducted in Argentina with nationwide representative sampling shows an increase in the frequency of non polymorphic resistance-associated mutations (RAMs) associated with resistance to NNTRI. This study generates the framework of evidence that supports the use of schemes based on high genetic barrier integrase inhibitors such as DTG as the first line of treatment and the need for the use of resistance test prior to prescribing schemes based on non-nucleoside inhibitors of reverse transcriptase. We report for the first time the presence of a natural polymorphism associated with the most prevalent viral recombinant form in Argentina that could have an impact on first-generation integrase inhibitors such as raltegravir

28 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
SWSANTIAGO Werbajh
SANTIAGO Werbajh
LLLuciana Larocca
Luciana Larocca
CCCarolina Carrillo
Carolina Carrillo
FSFabiana Stolowicz
Fabiana Stolowicz
LCLorena Ogas Castells
Lorena Ogas Castells
AVAdrián Alberto Vojnov
Adrián Alberto Vojnov
A large population has been infected by COVID-19 (Coronavirus disease-19) and it has been necessary a rapid and simple diagnostic method to detect the SARS-CoV-2and control its spread. We developed a colorimetric reverse transcription-loop-mediated isothermal amplification (RT-LAMP) kit that allow the detection of SARS-CoV-2 from nasopharyngeal swab samples without the need of RNA extraction. The kit utilizes three sets of LAMP primers targeting two regions of ORF1ab and one region in the E gene. The results are reported using colorimetric change of hydroxynaphthol blue, enabling visual interpretation without the need for expensive instrument. The kit demonstrated sensitivity to detect between 50 and 100 copies of the viral genome per reaction. The kit was authorized by the National Administration of Drugs, Food and Technology (ANMAT) of Argentina after validation using samples previously analyzed by gold standard RT-qPCR. The results showed sensitivity of 90,6 % and specificity of 100%, consistent with conventional RT-qPCR. In silico analysis confirmed the recognition of SARS-CoV-2 Variants of Concern (VOCs) B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.427, B.1.429and lineages of variant Omicron (B.1.1.529) with 100% homology. This rapid, simple, and sensitive RT-LAMP method paves a way for a large screening strategy to be carried out at locations lacking sophisticated-instrumental and trained-staff, as particularly happen at regional hospitals and medical centers from rural areas.

6 September 2022 in Public Health in Practice
Verified
Journal Article
Open access
MKM.A. Kundro
M.A. Kundro
MLM.H. Losso
M.H. Losso
AMA. Macchia
A. Macchia
IPI. Pastor
I. Pastor
MSM. Alonso Serena
M. Alonso Serena
FQF. Gonzalez B. de Quiros
F. Gonzalez B. de Quiros
In a context of COVID-19 vaccine shortages, this study sought to evaluate the safety and efficacy of receiving one dose of Gam-COVID-Vac rAd26 followed by a second COVID-19 vaccine dose of either Gam-COVID-Vac rAd5, ChAdOx1 nCoV-19 or BBIBP-CorV in a cohort of older adults. Single-centre, randomised, open label, non-inferiority trial. Adults aged ≥65 years who had received one dose of Gam-COVID-Vac rAd26 were randomised in a 1:1:1 ratio to receive a second-dose COVID-19 vaccination of either Gam-COVID-Vac rAd5, ChAdOx1 nCoV-19 or BBIBP-CorV. The primary outcome was the assessment of the humoral immune response to vaccination (i.e. antibody titres of SARS-CoV-2 spike protein at 28 days after second-dose vaccination). In addition, neutralising antibody titres at day 28 for the three schedules were measured. Of 85 participants who were enrolled in the study between 26 and July 30, 2021, 31 individuals were randomised to receive Gam-COVID-Vac rAd5, 27 to ChAdOx1 nCoV-19 and 27 to BBIBP-CorV. The mean age of participants was 68.2 years (SD 2.9) and 49 (57.6%) were female. Participants who received Gam-COVID-Vac rAd5 and ChAdOx1 nCoV1-19 showed significantly increased anti-S titres at 28 days after second-dose vaccination, but this magnitude of difference was not observed for those who received BBIBP-CorV. The ratio between the geometric mean at day 28 and baseline within each group was 11.8 (6.98–19.89) among patients assigned to Gam-COVID-Vac rAd26/rAd5, 4.81 (2.14–10.81) for the rAd26/ChAdOx1 nCoV-19 group and 1.53 (0.74–3.20) for the rAd26/BBIBP-CorV group. All of the schedules were shown to be safe. The findings in this study contribute to the scarce information published on the safety and immunogenicity of Gam-COVID-Vac heterologous regimens and will help the development of guidelines and vaccine programme management.

8 July 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
FSFederico R. Simioli
Federico R. Simioli
MBMaría Belen Bouzas
María Belen Bouzas
DMDana Mijalovsky
Dana Mijalovsky
MPMaria V. Pineda
Maria V. Pineda
LMLilia Mammana
Lilia Mammana
TOTomas A. Orduna
Tomas A. Orduna
In Argentina, the human T-cell lymphotropic virus type 1 (HTLV-1) infection has been documented mainly among blood banks with a prevalence of ~0.02–0.046% for Buenos Aires city, 0.8% for the northeast, and 1% for the northwest; both areas are considered endemic for HTLV-2 and 1, respectively. Policies and specific guidelines for testing blood donors for HTLV are included since 2005. Screening for antibodies is performed at blood banks and confirmatory testing is performed at reference laboratories. There are no specific recommendations for the assistance of communities and individuals affected, nor referral to specialized clinics on the HTLV infection. In 2016, as a strategy of intervention, we opened a specialized clinical attendance in a referral infectious diseases public hospital for the comprehensive approach to patients with HTLV, offering follow-up and counseling for patients and their families for the early diagnosis of HTLV-1/2 and related diseases. During the study, 124 patients with presumptive HTLV positive diagnosis from blood bank, symptomatic patients (SPs), relatives, and descendants visited the unit. A total of 46 patients were HTLV positive (38 HTLV-1 and 8 HTLV-2). There were nine SPs (2 adult T-cell leukemia/lymphoma [ATL] and 7 HTLV-1-associated myelopathy/tropical spastic paraparesis [HAM/TSP]). All patients with HTLV-1 and−2 were offered to study their relatives. Two out of 37 (5.4%) descendants tested were positive for HTLV-1. Sexual partners were studied; among 6 out of 11 couples (54.5%) were found positive (5 HTLV-1 and 1 HTLV-2). Other relatives, such as mothers (1/2) and siblings (1/6), were positive for HTLV-1. According to the place of birth among HTLV-1 carriers, 58% were born in an endemic area or in countries where HTLV infection is considered endemic while for HTLV-2 carriers, 12.5% were born in an endemic area of Argentina. The proviral load (pVL) was measured in all, patients with HTLV-1 being higher in symptomatic compared with asymptomatic carriers. In addition, two pregnant women were early diagnosed during their puerperium and breastmilk replacement by formula was indicated. Inhibition of lactation was also indicated. Our study provides tools for a multidisciplinary approach to the infection and reinforces the importance of having specialized clinical units in neglected diseases, such as HTLV for counseling, clinical and laboratory follow-up, and providing useful information for patients for self-care and that of their families.